Discover how Ergomed’s orphan drug team ensured a newly-enrolled Wilson’s Disease patient could participate in a Phase II/III Study while celebrating her honeymoon.
With weekly safety lab tests required during this critical period, Ergomed coordinated with a clinic in Cyprus to provide seamless, local blood-draws and ongoing monitoring, allowing her to continue the trial safely.
Download the full case study to see how Ergomed’s patient-centered approach and flexible solutions support rare disease trials, empowering patients to live fully while participating in essential research.
